At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 148 enrolled
Drug / intervention
Cyclophosphamide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
In Brief
A Phase 2 clinical trial evaluating Cyclophosphamide, Ixazomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 148 participants across 24 sites in 5 countries.
Detailed Summary
This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Greece, Poland, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionJun 2018
TodayJul 2026
First PostedJan 27, 2014
Enrollment StartMar 5, 2014
Primary CompletionJun 29, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.4 years ago
Interventions
Cyclophosphamidedrug
Cyclophosphamide tablets
Ixazomibdrug
Ixazomib capsules
Dexamethasonedrug
Dexamethasone tablets